Abstract
THIS is the second of a two-part article on the results of randomized trials of treatments designed to reduce mortality or major morbidity in heart disease. Our goal is to summarize the results of trials of common treatments on major outcomes in unstable angina, congestive heart failure, primary prevention with aspirin, and risk factor modification. This summary should provide useful background information against which clinicians must consider other information (eg, patient prognosis, risk of side effects, drug interactions, and specific clinical picture) in making decisions about individual patients. We do not deal in either article with trials of coronary artery bypass graft surgery for stable angina, trials of valve replacement, or congenital heart disease. The risk reductions are based on the odds ratio calculated by the Mantel-Haenszel method as applied to combining data from several trials. When event rates are low, the odds ratio and the relative risk are numerically
Keywords
Related Publications
Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials
<h3>Objective.</h3> —To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitors on mortality and morbidity in patients with symptomatic congestive heart failure. <...
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction
The presence of viable myocardium was associated with a greater likelihood of survival in patients with coronary artery disease and left ventricular dysfunction, but this relati...
High Blood Pressure and Cardiovascular Disease
Fragmented investigation has masked the overall picture for causes of cardiovascular disease (CVD). Among the risk factors for CVD, high blood pressure (BP) is associated with t...
Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice
Background— There is a paucity of international data on the various types of atrial fibrillation (AF) outside the highly selected populations from randomized trials. This study ...
Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists
Background —Numerous clinical trials have established the benefits of intravenous glycoprotein IIb/IIIa inhibition in the management of coronary artery disease. In contrast, the...
Publication Info
- Year
- 1988
- Type
- article
- Volume
- 260
- Issue
- 15
- Pages
- 2259-2263
- Citations
- 267
- Access
- Closed
External Links
Social Impact
Social media, news, blog, policy document mentions
Citation Metrics
Cite This
Identifiers
- DOI
- 10.1001/jama.260.15.2259